7 / 20
Page 20
Notes:
allied
academies
September 20-21, 2017 | Philadelphia, USA
Global summit on
TUBERCULOSIS AND LUNG DISEASE
Int J Respir Med 2017 Volume 2 Issue 2
Suppressor cell-targeted immunotherapy with denileukin diftitox improves tuberculosis treatment
Shashank Gupta
Brown University, USA
C
urrent therapies for tuberculosis (TB) are problematic due
to emerging drug resistance, toxicity, and the need for
prolonged treatment. Host-directed therapies that augment
host immune effector mechanisms may serve as important
adjunctive therapies for tuberculosis treatment. Regulatory
T cells and myeloid derived suppressor cells are important
populations of cells that are induced during TB infection and
can suppress the effector T cell response. We evaluated a
recombinant fusion protein toxin, denileukin difititox (DD),
as a host-directed immunotherapy in an acute mouse model
of TB infection and analyzed the cellular composition and
bacterial burden in lungs and spleens. The
in vivo
studies
in Balb/c mice indicate that DD administration results in
reduced bacterial proliferation during lung infection and
augments the effect of standard TB drugs in the mouse
model. This beneficial effect is likely due to its activity in
depleting regulatory T cells and other cells that express
high levels of CD25 during TB infection. Our results indicate
that denileukin diftitox and other suppressor cell–depleting
therapies may be useful adjunctive, host-directed therapies
for TB.
Speaker Biography
Shashank Gupta is currently working in Brown University, USA and he has previously
worked on tuberculosis in Johns Hopkins Medicine.
e:
shashank.honey@gmail.com